bis(2-tetrahydrofuranylmethyl)carbonate | 100053-67-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: bis(2-tetrahydrofuranylmethyl)carbonate
• 英文别名: ditetrahydrofurfuryl carbonate；DTC；carbonic acid bis-tetrahydrofurfuryl ester；Kohlensaeure-bis-tetrahydrofurfurylester；bis(oxolan-2-ylmethyl) carbonate
• CAS: 100053-67-6
• 化学式: C₁₁H₁₈O₅
• 分子量: 230.261
• InChiKey: BEGJLONJWKRQQM-UHFFFAOYSA-N

物化性质

• 沸点：
  329.5±7.0 °C(Predicted)
• 密度：
  1.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  bis(2-tetrahydrofuranylmethyl)carbonate 、 乙炔 、 alkaline earth salt of/the/ methylsulfuric acid 生成 3,3-bis-tetrahydrofurfuryloxy-propionic acid tetrahydrofurfuryl ester
  参考文献：
  名称：

  US2535012

  摘要：

  公开号：
• 作为产物：
  描述：

  双[(四氢呋喃-2-基)甲氧基]二氟甲烷 在 水 作用下， 生成 bis(2-tetrahydrofuranylmethyl)carbonate
  参考文献：
  名称：

  Constructing the OCF₂O Moiety Using BrF₃

  摘要：

  A general preparation for aromatic and aliphatic, cyclic as well as linear, symmetric and asymmetric difluoromethylenedioxy derivatives is described. The alcohols were reacted with thiophosgene to give thiocarbonates, which in turn were reacted with BrF(3). The fluorination step is complete in seconds with moderate to high yields under mild conditions.

  DOI：

  10.1021/jo801116n

文献信息

• [EN] AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE<br/>[FR] COMPOSES DE TYPE AZOLE, LEUR PRODUCTION ET LEUR UTILISATION
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：WO1998043970A1

  公开（公告）日：1998-10-08

  (EN) A quaternized nitrogen-containing imidazol-1-yl or 1,2,4-triazol-1-yl compound wherein one of nitrogen atoms constituting an azole ring is quaternized with a substituent capable of being eliminated $i(in vivo) and the substituent can be eliminated $i(in vivo) to be converted into an antifungal azole compound, have an improved solubility in water, can advantageously be applied to injection, have an improved internal absorption and can be expected to have a good effect for the treatment or prevention of disease.(FR) L'invention concerne un composé d'imidazol-1-yl ou 1,2,4-triazol-1-yl contenant du nitrogène et quaternarisé, dans lequel un des atomes de nitrogène constituant un noyau d'azole est quaternarisé avec un substituant capable d'être éliminé in vivo, le substituant pouvant être éliminé in vivo de manière à être transformé en un composé de type azole antifongique; ce composé possède une solubilité améliorée dans l'eau, peut être appliqué de manière avantageuse par injection, possède une capacité améliorée d'absorption interne et est capable de présenter un effet bénéfique dans le traitement ou la prévention d'affections.

  一种四元氮含量咪唑-1-基或1,2,4-三唑-1-基化合物，其中构成咪唑环的氮原子之一与能够在体内被消除的取代基进行季铵化，该取代基能够在体内被消除以转化为抗真菌咪唑化合物，具有改善的水溶性，可优势地应用于注射，具有改善的内部吸收能力，并可望在治疗或预防疾病方面产生良好的效果。
• MACROCYCLES AS FACTOR XIA INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20150112058A1

  公开（公告）日：2015-04-23

  The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了I式化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量均如此处所定义。这些化合物是选择性因子XIa抑制剂或fXIa和血浆卡利肽酶的双重抑制剂。本发明还涉及包含这些化合物的制药组合物和使用它们治疗血栓栓塞性和/或炎症性疾病的方法。
• A polymeric article, such as a medical catheter, and method for making the same
  申请人：NAMIC CARIBE, INC.

  公开号：EP0514913A2

  公开（公告）日：1992-11-25

  A polymeric article and method for making a polymeric article, such as a catheter, are disclosed wherein the article is contacted with a swelling agent, such as a solvent, and a plasticizer to make the polymeric material softer and/or more pliable or flexible. The contacting may be carried our sequentially or simultaneously, using a solution comprising a plasticizer and a solvent.

  本发明公开了一种聚合制品和聚合制品（如导管）的制造方法，其中聚合制品与溶胀剂（如溶剂）和增塑剂接触，使聚合材料更柔软和/或更柔韧或有弹性。这种接触可先后或同时进行，使用的溶液包括增塑剂和溶剂。
• ANTIMYCOTIC DRUG COMPOSITION
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1120116A1

  公开（公告）日：2001-08-01

  The composition of the present invention comprises a quaternized nitrogen-containing imidazole-1-yl or 1,2,4-triazole-1-yl compound wherein one of the nitrogen atoms constituting the azole ring is quaternized with a group eliminating in vivo and represented by the formula: wherein R1 represents a hydrocarbon or heterocyclic group which may be substituted, R2 represents a hydrogen atom or a lower alkyl group, and n is 0 or 1, and a saccharide, said compound being capable of being converted into an anti-fungal azole compound upon elimination of said group in vivo. The composition of the present invention is stable and usable particularly as a pharmaceutical preparation for an injection composition.

  本发明的组合物包括一种季铵化的含氮咪唑-1-基或 1,2,4-三唑-1-基化合物，其中构成唑环的一个氮原子被一种在体内消除的基团季铵化，并由式表示： 其中 R1 代表可被取代的烃基或杂环基，R2 代表氢原子或低级烷基，n 为 0 或 1，以及一种糖类，所述化合物在体内消除所述基团后可转化为抗真菌唑类化合物。本发明的组合物性质稳定，尤其可用作注射组合物的药物制剂。
• SYNTHETIC INTERMEDIATES FOR PRODUCING MACROCYCLES AS FACTOR XIA INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3786165A1

  公开（公告）日：2021-03-03

  The present invention provides synthetic intermediates useful in the preparation of compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor Xia inhibitors or dual inhibitors of fXIa and plasma kallikrein.

  本发明提供了用于制备式（I）化合物或其立体异构体、同分异构体或药学上可接受的盐的合成中间体，其中所有变量如本文所定义。这些化合物是选择性夏因子抑制剂或 fXIa 和血浆钙激酶的双重抑制剂。